Phase 2 Metastatic Solid Tumor Clinical Trials
7 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–7 of 7 trials
Recruiting
Phase 1Phase 2
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
Metastatic Solid TumorSolid Tumor, AdultUnresectable Solid Tumor+1 more
Frontier Medicines Corporation403 enrolled26 locationsNCT06244771
Recruiting
Phase 1Phase 2
GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
Cervical CancerUrothelial CarcinomaAdvanced Solid Tumor+3 more
GI Innovation, Inc.317 enrolled8 locationsNCT04977453
Recruiting
Phase 1Phase 2
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Ovarian CancerEndometrial CancerProstate Cancer+5 more
PMV Pharmaceuticals, Inc300 enrolled76 locationsNCT04585750
Recruiting
Phase 1Phase 2
A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors
Pancreatic CancerNon-small Cell Lung Cancer (NSCLC)Advanced Solid Tumor+3 more
GI Innovation, Inc.76 enrolled3 locationsNCT07172802
Recruiting
Phase 1Phase 2
Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors
Metastatic Solid TumorLocally Advanced Solid TumorEGFR Overexpression
Yuhan Corporation80 enrolled4 locationsNCT06975410
Recruiting
Phase 1Phase 2
Study of LP-184 in Patients With Advanced Solid Tumors
Advanced Solid TumorMetastatic Solid TumorTNBC - Triple-Negative Breast Cancer+4 more
Lantern Pharma Inc.175 enrolled9 locationsNCT05933265
Recruiting
Phase 1Phase 2
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
Advanced Solid TumorMetastatic Solid TumorSoft Tissue Sarcoma (STS)+3 more
GI Innovation, Inc.358 enrolled11 locationsNCT05824975